What question did this study set out to answer?

To engineer an anti-CD20 single chain variable fragment–apolipoprotein A-I fusion protein and evaluate whether nanodisks assembled with this chimera can selectively deliver bioactive agents to lymphoma cells.

April 20, 2015Biochemistry and Cell BiologyOpen Access

Anti-CD20 single chain variable antibody fragment–apolipoprotein A-I chimera containing nanodisks promote targeted bioactive agent delivery to CD20-positive lymphomas

View Full Paper

Ask AI

Bookmark

Authors

NCNatasha M. Crosby MGMistuni GhoshAgilent Technologies (United States)BSBetty Su

Discussion

Member takes

Implication

In vitro study demonstrates targeted delivery and cytotoxic action of antibody-guided nanodisks in lymphoma cells, indicating a strategy to reduce off-target chemotherapy toxicity.

Key Points

To engineer an anti-CD20 single chain variable fragment–apolipoprotein A-I fusion protein and evaluate whether nanodisks assembled with this chimera can selectively deliver bioactive agents to lymphoma cells.
Constructed and expressed an α-CD20 scFv–spacer–apoA-I fusion protein in Escherichia coli and formulated it into reconstituted high-density lipoprotein nanodisks.
Evaluated target binding using CD20-positive non-Hodgkin lymphoma lines (Ramos, Granta) and a CD20-negative control line (Jurkat), with rituximab pre-incubation to assess competitive inhibition.
Loaded nanodisks with curcumin and monitored cellular localization and cytotoxicity using confocal fluorescence microscopy and cell viability assays.
α-CD20 scFv•apoA-I nanodisks bound specifically to CD20-positive Ramos and Granta cells, an interaction partially blocked by rituximab, while showing no binding to CD20-negative Jurkat cells.
Confocal microscopy demonstrated that the nanodisk scaffold localized to the lymphoma cell surface while curcumin off-loaded into the cytoplasm, significantly decreasing cell viability compared to control treatments.

Cite This Study

Crosby et al. (2015) studied this question.

synapsesocial.com/papers/6a95c1610d97b8993d2bf0cb https://doi.org/10.1139/bcb-2015-0009

View Full Paper

Ask AI

Bookmark

Implication

In vitro study demonstrates targeted delivery and cytotoxic action of antibody-guided nanodisks in lymphoma cells, indicating a strategy to reduce off-target chemotherapy toxicity.

Anti-CD20 single chain variable antibody fragment–apolipoprotein A-I chimera containing nanodisks promote targeted bioactive agent delivery to CD20-positive lymphomas

Discussion

Member takes

Implication

Key Points

Cite This Study

Anti-CD20 single chain variable antibody fragment–apolipoprotein A-I chimera containing nanodisks promote targeted bioactive agent delivery to CD20-positive lymphomas

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider